Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a Phase 2/3 clinical trial of Glassia®, the Company’s proprietary human Alpha-1 Antitrypsin (AAT), to treat newly diagnosed pediatric patients…
Source:Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D
Wednesday, March 5, 2014
Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment